Decreased expression of the reduced folate carrier and folypolyglutamate synthetase is the basis for acquired resistance to the pemetrexed antifolate (LY231514) in an L1210 murine leukemia cell lineYANHUA WANG; RONGBOA ZHAO; GOLDMAN, I. David et al.Biochemical pharmacology. 2003, Vol 65, Num 7, pp 1163-1170, issn 0006-2952, 8 p.Article

The AntifolatesVISENTIN, Michele; RONGBAO ZHAO; GOLDMAN, I. David et al.Hematology/oncology clinics of North America. 2012, Vol 26, Num 3, issn 0889-8588, ix, 629-648 [21 p.]Article

Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agentADJEI, Alex A.Clinical cancer research. 2004, Vol 10, Num 12, pp 4276s-4280s, issn 1078-0432, 2Conference Paper

Méthotrexate = MethotrexateCAPPELAERE, P; ARMAND, J.-P.Gazette médicale de France (1969). 1986, pp 15-16, issn 0016-5557, suppl. no 42Article

Intoxication grave au méthotrexateTROCHE, G; SACQUIN, P; ACHKAR, A et al.La Presse médicale (1983). 1991, Vol 20, Num 35, pp 1724-1727, issn 0755-4982Article

Ode to methotrexateBERTINO, J. R.Journal of clinical oncology. 1993, Vol 11, Num 1, pp 5-14, issn 0732-183XArticle

5-Amino-4-lmidazolecarboxamide riboside potentiates both transport of reduced folates and antifolates by the human reduced folate carrier and their subsequent metabolismMCGUIRE, John J; HAILE, William H; YEH, Chen-Chen et al.Cancer research (Baltimore). 2006, Vol 66, Num 7, pp 3836-3844, issn 0008-5472, 9 p.Article

Synergistic interaction between methotrexate and a superoxide dismutase mimetic : Pharmacologic and potential clinical significanceCUZZOCREA, Salvatore; MAZZON, Emanuela; DI PAOLA, Rosanna et al.Arthritis and rheumatism. 2005, Vol 52, Num 12, pp 3755-3760, issn 0004-3591, 6 p.Article

Structural features of 4-amino antifolates required for substrate activity with mammalian folylpolyglutamate synthetaseMORAN, R. G; COLMAN, P. D; ROSOWSKY, A et al.Molecular pharmacology. 1985, Vol 27, Num 1, pp 156-166, issn 0026-895XArticle

Les stratégies d'utilisation du méthotrexateWENDLING, Daniel.Rhumatos. 2010, Vol 7, Num 60, pp 2-4, issn 1771-0081, 3 p., CAH2Article

Antifolate resistance in a HeLa cell line associated with impaired transport independent of the reduced folate carrierRONGBAO ZHAO; CHATTOPADHYAY, Shrikanta; HANSCOM, Marie et al.Clinical cancer research. 2004, Vol 10, Num 24, pp 8735-8742, issn 1078-0432, 8 p.Article

The renewed potential for folate antagonists in contemporary cancer chemotherapyBERMAN, E. M; WERBEL, L. M.Journal of medicinal chemistry (Print). 1991, Vol 34, Num 2, pp 479-485, issn 0022-2623, 7 p.Article

Anticancer drug development at Lilly Research Laboratories. DiscussionPEARCE, H. L; HART, I.Annals of oncology. 1995, Vol 6, pp S55-S62, issn 0923-7534, SUP1Conference Paper

An investigation into the source of the deglutamated metabolites of methotrexate in patients treated with high dose infusionsSTEWART, M. J; WATSON, I. D; FARID, Y. Y. Z et al.Annals of clinical biochemistry. 1986, Vol 23, Num 2, pp 210-215, issn 0004-5632Article

A fluorescent analogue of methotrexate as a probe for folate antagonist molecular receptorsSUSTEN, S. S; KEMPTON, R. J; BLACK, A. M et al.Biochemical pharmacology. 1984, Vol 33, Num 12, pp 1957-1962, issn 0006-2952Article

Persistence of antifolate activity in skin of rats following systemic administration of methotrexateZIMMERMAN, C. L; FRANZ, T. J; SLATTERY, J. T et al.Journal of investigative dermatology. 1984, Vol 82, Num 1, pp 57-61, issn 0022-202XArticle

Antifolates targeted specifically to the folate receptorJACKMAN, Ann L; THETI, Davinder S; GIBBS, David D et al.Advanced drug delivery reviews. 2004, Vol 56, Num 8, pp 1111-1125, issn 0169-409X, 15 p.Article

2,4-diaminopteridine-based compounds as precursors for de novo synthesis of antifolates : a novel class of antimalarialsNDUATI, Eunice; HUNT, Sonya; KAMAU, Eddy M et al.Antimicrobial agents and chemotherapy. 2005, Vol 49, Num 9, pp 3652-3657, issn 0066-4804, 6 p.Article

Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphomaO'CONNOR, Owen A; HAMLIN, Paul A; MOULD, Diane R et al.British journal of haematology. 2007, Vol 139, Num 3, pp 425-428, issn 0007-1048, 4 p.Article

Antifolate pseudo-resistance due to elevated levels of thymidine and hypoxanthine in a commercial serum preparationSIMON, Marcel; BLATTER, Johannes; GRANZOW, Christof et al.Anticancer research. 2007, Vol 27, Num 2, pp 769-773, issn 0250-7005, 5 p.Article

Éléments prédictifs de la réponse thérapeutique au méthotrexateCANTAGREL, Alain.Revue du rhumatisme (Ed. française). 2010, Vol 77, pp 4-9, issn 1169-8330, 6 p., HS1Article

Initiative 3 E: Evidence, Expertise, ExchangeWENDLING, Daniel.Rhumatos. 2010, Vol 7, Num 58, pp 5-6, issn 1771-0081, 2 p., CAH3Article

Methotrexate for psoriasis in the era of biological therapyWARREN, R. B; CHALMERS, R. J. G; GRIFFITHS, C. E. M et al.Clinical and experimental dermatology (Print). 2008, Vol 33, Num 5, pp 551-554, issn 0307-6938, 4 p.Article

Foie et méthotrexate = The liver and methotrexateLAHANE, D; TERREBONNE, E; VERGNIOL, J et al.Gastroentérologie clinique et biologique. 2008, Vol 32, Num 2, pp 134-142, issn 0399-8320, 9 p.Article

Early identification of resistance to first-line single-agent methotrexate in patients with persistent trophoblastic diseaseVAN TROMMEL, Nienke E; MASSUGER, Leon F; SCHIJF, Charles P et al.Journal of clinical oncology. 2006, Vol 24, Num 1, pp 52-58, issn 0732-183X, 7 p.Article